Registry Search

AMINOSYN-HBC 7%

Comprehensive clinical and safety monograph for AMINOSYN-HBC 7% (AMINOSYN-HBC 7%).

AMINOSYN-HBC 7% IN PLASTIC CONTAINER

Comprehensive clinical and safety monograph for AMINOSYN-HBC 7% IN PLASTIC CONTAINER (AMINOSYN-HBC 7% IN PLASTIC CONTAINER).

AMINOSYN-HF 8%

Comprehensive clinical and safety monograph for AMINOSYN-HF 8% (AMINOSYN-HF 8%).

AMINOSYN-PF 10%

Comprehensive clinical and safety monograph for AMINOSYN-PF 10% (AMINOSYN-PF 10%).

AMINOSYN-PF 7%

Comprehensive clinical and safety monograph for AMINOSYN-PF 7% (AMINOSYN-PF 7%).

AMINOSYN-RF 5.2%

Comprehensive clinical and safety monograph for AMINOSYN-RF 5.2% (AMINOSYN-RF 5.2%).

AMIPAQUE

Comprehensive clinical and safety monograph for AMIPAQUE (AMIPAQUE).

AMITID

Comprehensive clinical and safety monograph for AMITID (AMITID).

AMITIZA

Comprehensive clinical and safety monograph for AMITIZA (AMITIZA).

AMITRIL

Comprehensive clinical and safety monograph for AMITRIL (AMITRIL).

AMITRIPTYLINE HYDROCHLORIDE

MAOIs can cause serotonin syndrome and hyperpyrexia Strong anticholinergic effects may occur with other drugs like benztropine Increased risk of suicide in children and young adults.

AMJEVITA

Comprehensive clinical and safety monograph for AMJEVITA (AMJEVITA).

AMLEXANOX

Comprehensive clinical and safety monograph for AMLEXANOX (AMLEXANOX).

AMLODIPINE AND OLMESARTAN MEDOXOMIL

NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Use in pregnancy can cause injury and death to the developing fetus.

AMLODIPINE BENZOATE

Weak CYP3A4 inhibitors may increase levels but no dosage adjustment is typically needed Monitor for hypotension and peripheral edema dose-related side effects.

AMLODIPINE BESYLATE

Weak CYP3A4 inhibitors may increase levels but no dosage adjustment is typically needed Monitor for hypotension and peripheral edema dose-related side effects.

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

Weak CYP3A4 inhibitors may increase levels but no dosage adjustment is typically needed Monitor for hypotension and peripheral edema dose-related side effects.

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Risk of angioedema can occur at any time discontinue immediately.

AMLODIPINE BESYLATE AND VALSARTAN

NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Use in pregnancy can cause injury and death to the developing fetus.

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Use in pregnancy can cause injury and death to the developing fetus.

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Risk of angioedema can occur at any time discontinue immediately.

AMLODIPINE MALEATE; BENAZEPRIL HYDROCHLORIDE

NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Risk of angioedema can occur at any time discontinue immediately.

AMMONIA N 13

Comprehensive clinical and safety monograph for AMMONIA N 13 (AMMONIA N 13).

AMMONIUM CHLORIDE

Comprehensive clinical and safety monograph for AMMONIUM CHLORIDE (AMMONIUM CHLORIDE).

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

Comprehensive clinical and safety monograph for AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE (AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE).

AMMONIUM CHLORIDE 2.14%

Comprehensive clinical and safety monograph for AMMONIUM CHLORIDE 2.14% (AMMONIUM CHLORIDE 2.14%).

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

Comprehensive clinical and safety monograph for AMMONIUM CHLORIDE IN PLASTIC CONTAINER (AMMONIUM CHLORIDE IN PLASTIC CONTAINER).

AMMONIUM LACTATE

Comprehensive clinical and safety monograph for AMMONIUM LACTATE (AMMONIUM LACTATE).

AMMONUL

Comprehensive clinical and safety monograph for AMMONUL (AMMONUL).

AMNESTEEM

Comprehensive clinical and safety monograph for AMNESTEEM (AMNESTEEM).

AMNESTROGEN

Comprehensive clinical and safety monograph for AMNESTROGEN (AMNESTROGEN).

AMONDYS 45

Comprehensive clinical and safety monograph for AMONDYS 45 (AMONDYS 45).

AMOSENE

Comprehensive clinical and safety monograph for AMOSENE (AMOSENE).

AMOXAPINE

Comprehensive clinical and safety monograph for AMOXAPINE (AMOXAPINE).

AMOXICILLIN

Probenecid decreases renal tubular secretion of amoxicillin May reduce efficacy of oral contraceptives Serious and occasionally fatal hypersensitivity reactions have been reported.

AMOXICILLIN AND CLAVULANATE POTASSIUM

Probenecid decreases renal tubular secretion of amoxicillin May reduce efficacy of oral contraceptives Serious and occasionally fatal hypersensitivity reactions have been reported.

AMOXICILLIN PEDIATRIC

Probenecid decreases renal tubular secretion of amoxicillin May reduce efficacy of oral contraceptives Serious and occasionally fatal hypersensitivity reactions have been reported.

Amoxicillin-Clavulanate

Amoxicillin-clavulanate is a broad-spectrum oral antibiotic combining a penicillin with a beta-lactamase inhibitor. It is generally considered safe in pregnancy for standard indications such as urinary tract infections, skin and soft tissue infections, and community-acquired respiratory infections. However, the landmark ORACLE I randomised controlled trial (Kenyon et al., Lancet 2001) demonstrated a statistically significant increase in necrotising enterocolitis (NEC) in neonates born to mothers who received co-amoxiclav for preterm prelabour rupture of membranes (PPROM). Consequently, erythromycin (or azithromycin) is the preferred antibiotic for PPROM latency therapy. Outside the PPROM context, the overall risk-benefit profile remains favourable in pregnancy.

AMOXIL

Comprehensive clinical and safety monograph for AMOXIL (AMOXIL).

AMPHADASE

Comprehensive clinical and safety monograph for AMPHADASE (AMPHADASE).

AMPHETAMINE

MAOIs can cause hypertensive crisis Alkalinizing agents increase urinary excretion and acidifying agents decrease it High potential for abuse and dependence.

AMPHETAMINE SULFATE

MAOIs can cause hypertensive crisis Alkalinizing agents increase urinary excretion and acidifying agents decrease it High potential for abuse and dependence.

AMPHOTEC

Comprehensive clinical and safety monograph for AMPHOTEC (AMPHOTEC).

AMPHOTERICIN B

Comprehensive clinical and safety monograph for AMPHOTERICIN B (AMPHOTERICIN B).

Ampicillin

Ampicillin is a broad-spectrum aminopenicillin antibiotic with an established safety record across all trimesters of pregnancy. It is the first-line intravenous agent for Group B Streptococcus (GBS) intrapartum prophylaxis per CDC and ACOG guidelines, the drug of choice (in combination with gentamicin) for treatment of listeriosis in pregnancy, and a standard agent for urinary tract infections, chorioamnionitis regimens, and endocarditis prophylaxis in obstetric patients. No teratogenic signal has been identified in large epidemiological cohorts. It does not carry the necrotising enterocolitis (NEC) risk associated with amoxicillin-clavulanate in PPROM. Oral bioavailability is limited and erratic; the IV/IM route is standard for serious obstetric indications.

AMPICILLIN AND SULBACTAM

Probenecid decreases renal tubular secretion of ampicillin Allopurinol may increase the incidence of skin rashes Serious and occasionally fatal hypersensitivity reactions have been reported.

AMPICILLIN SODIUM

Probenecid decreases renal tubular secretion of ampicillin Allopurinol may increase the incidence of skin rashes Serious and occasionally fatal hypersensitivity reactions have been reported.

AMPICILLIN TRIHYDRATE

Probenecid decreases renal tubular secretion of ampicillin Allopurinol may increase the incidence of skin rashes Serious and occasionally fatal hypersensitivity reactions have been reported.

AMPYRA

Comprehensive clinical and safety monograph for AMPYRA (AMPYRA).

AMRINONE LACTATE

Comprehensive clinical and safety monograph for AMRINONE LACTATE (AMRINONE LACTATE).